NCT07064018View on ClinicalTrials.gov

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2031

Conditions
Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung CancerCervical CancerOvarian CancerKRAS Mutation-Related Tumors
Interventions
DRUG

Spedox-6

Given Intravenously (IV)

DRUG

Pegfilgrastim

Given Subcutaneous Injection or IV

DRUG

Filgrastim

Given Subcutaneous Injection or IV

Trial Locations (1)

92868

RECRUITING

Chao Family Comprehensive Cancer Center University of California, Irvine, Orange

All Listed Sponsors
collaborator

Sunstate Biosciences LLC

INDUSTRY

lead

University of California, Irvine

OTHER